{"id":"068746c80bb8","type":"article","url":"https://hartvaat.nl/2026/09/01/glp-1-agonisten-verlagen-mace-en-hartfalen-heropnames-bij-diabetes-en-ascvd-meta/","title":"GLP-1-agonisten verlagen MACE en hartfalen-heropnames bij diabetes en ASCVD — meta-analyse","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Cardiovascular endocrinology & metabolism","doi":"10.1097/XCE.0000000000000360","source_url":"https://doi.org/10.1097/XCE.0000000000000360","authors":["Alejandro Montenegro-Avila","Abelardo Montenegro-Cantillo","Jheyson Fuentes","Jennifer Cifuentes","German Camilo Giraldo-Gonzalez"],"significance":6,"published":"2026-07-26","source_date":"2026-09-01","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/glp1-agonisten-cardiologie/","https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/"],"congress":"","summary_en":"A systematic review and meta-analysis of seven randomised trials (n=56,191) demonstrates that GLP-1 receptor agonists significantly reduce major adverse cardiovascular events by 11% (HR 0.89; 95% CI 0.83–0.96) in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. The intervention also lowered all-cause mortality by 11% (HR 0.89; 95% CI 0.82–0.97) and heart failure hospitalisations by 7% (HR 0.93; 95% CI 0.89–0.98), with high-certainty evidence across outcomes. Incorporating recent data from the SOUL trial and oral formulations, these findings reinforce the established cardiovascular benefits of GLP-1RAs and support their continued integration into cardiometabolic care pathways.","created":"2026-07-04T15:52:23Z","updated":"2026-08-10T10:38:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Een systematische review en meta-analyse van zeven RCT's (n=56.191) toont aan dat GLP-1-agonisten bij volwassenen met type 2-diabetes en vaststaande atherosclerotische cardiovasculaire ziekte het risico op MACE met 11% verlagen (HR 0,89; 95% BI 0,83-0,96). Ook de all-cause mortality daalde met 11% (HR 0,89; 95% BI 0,82-0,97) en hartfalen-heropnames met 7% (HR 0,93; 95% BI 0,89-0,98), met bewijs van hoge zekerheid. Deze bevindingen, die recent data van onder meer de SOUL-trial en orale formuleringen omvatten, onderstrepen de cardiovasculaire meerwaarde van GLP-1-agonisten in deze hoogrisicogroep en ondersteunen hun plaats in de huidige behandelrichtlijnen.","abstract_original":"Cardiovascular outcome trials suggest that glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events in individuals with type 2 diabetes (T2DM), but the magnitude of benefit, including recent evidence from the landmark SOUL trial and oral formulations, remains uncertain. We performed a Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 (International Prospective Register of Systematic Reviews ID: CRD420251034652), searching PubMed, Embase, Cochrane CENTRAL, Scopus and ClinicalTrials.gov on 6 May 2025 for randomised controlled trials comparing GLP-1RAs with placebo or usual care in adults with T2DM and established atherosclerotic cardiovascular disease. Seven trials, including 56 191 participants (mean follow-up: 3.5 years), were analysed. GLP-1RAs reduced major adverse cardiovascular events by 11% [hazard ratio: 0.89, 95% confidence interval (CI): 0.83-0.96], all-cause mortality by 11% (hazard ratio: 0.89, 95% CI: 0.82-0.97) and hospitalisation for heart failure by 7% (hazard ratio: 0.93, 95% CI: 0.89-0.98), all with high-certainty evidence. Overall, GLP-1RAs - available in subcutaneous and oral formulations - provide clinically meaningful cardiovascular benefits in high-risk adults with T2DM."}